Glaukos Co. (NYSE:GKOS) Short Interest Update

Glaukos Co. (NYSE:GKOS - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,040,000 shares, an increase of 18.3% from the December 31st total of 2,570,000 shares. Based on an average daily trading volume, of 567,300 shares, the short-interest ratio is currently 5.4 days.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently bought and sold shares of the company. Williamson Legacy Group LLC acquired a new position in shares of Glaukos during the fourth quarter valued at approximately $868,000. US Bancorp DE boosted its holdings in shares of Glaukos by 8.3% during the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier's stock worth $914,000 after purchasing an additional 470 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after purchasing an additional 89 shares in the last quarter. Versor Investments LP increased its holdings in shares of Glaukos by 55.3% in the fourth quarter. Versor Investments LP now owns 5,442 shares of the medical instruments supplier's stock valued at $816,000 after purchasing an additional 1,938 shares during the last quarter. Finally, New York Life Investment Management LLC purchased a new position in Glaukos during the fourth quarter worth approximately $848,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Price Performance

Shares of NYSE:GKOS traded up $3.07 during midday trading on Wednesday, reaching $157.39. 381,884 shares of the company's stock traded hands, compared to its average volume of 531,167. The company has a market cap of $8.68 billion, a P/E ratio of -52.12 and a beta of 1.04. The company has a fifty day simple moving average of $149.95 and a two-hundred day simple moving average of $136.67. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a 1 year low of $83.90 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same quarter last year, the business earned ($0.50) earnings per share. The company's revenue for the quarter was up 23.9% compared to the same quarter last year. Equities analysts predict that Glaukos will post -1.89 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Piper Sandler reiterated an "overweight" rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Wells Fargo & Company increased their price objective on shares of Glaukos from $145.00 to $153.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. BTIG Research upped their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Morgan Stanley lowered Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a research note on Monday, December 2nd. Finally, Truist Financial upped their target price on Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus target price of $151.08.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.